Up to now, research has largely focused on how the mutated gene, Myc, disrupts the ability of DNA to be "transcribed" into RNA - the first step in making proteins that are essential for cell growth and function. But the new research shows that this altered Myc gene, called an oncogene, can also act directly on the final stage of protein production.
The finding in mice suggests that drugs already available to counter this increased protein production could slow or stop cancer's runaway growth induced by Myc. Rapamycin, for example, an immunosuppressant drug already in clinical trials for cancer, might help treat cancers where Myc is over active, the scientists suggest.